Pilot study of interferon-α high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C

Zeitschrift fur Gastroenterologie

Volumn 39, Issue 2, 2001, Pages 145-151

  Berg, T ^a   Naumann, U ^a   Wiedenmann, B ^a   Hopf, U ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Amantadine; Hepatitis C virus kinetics; High dose interferon ; Ribavirin; Triple therapy

Indexed keywords

ALPHA INTERFERON; AMANTADINE; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; BRONCHITIS; CHRONIC HEPATITIS; CLINICAL ARTICLE; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; HYPOTHYROIDISM; MALE; PILOT STUDY; RELAPSE; TREATMENT OUTCOME; TREATMENT PLANNING; VIREMIA; WEIGHT REDUCTION;

ADULT; AGED; AMANTADINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; RETREATMENT; RIBAVIRIN; TREATMENT OUTCOME;

EID: 0035126916     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-11154     Document Type: Article

References (38)

1. Therapy of hepatitis C: Re-treatment with alpha interferon
2. A pilot study of ribavirin and interferon beta for the retreatment of chronic hepatitis C
3. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and nonresponders: Italian experience
4. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone
5. Interferon-ribavirin combination therapy for chronic hepatitis C
6. Retreatment wit interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C
7. Ribavirin and interferon-alpha combination therapy vs. interferon-alpha alone in the treatment of chronic hepatitis C: A randomized clinical trial
8. Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated? An analysis of personal experiences and review of the literature
9. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: A randomized trial
10. Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: Results of a randomized multicenter trial
11. A randomized trial of ribavirin and interferon-alpha in patients with chronic hepatitis C who were nonresponders to a previous treatment. Multicenter Study Group under the coordination of Necker Hospital, Paris, France
12. Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy
13. Treatment of chronic hepatitis C with amantadine
14. The roles of amantadine, rimatadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C
15. A pilot study of interferon plus amantadine versus interferon alone in the treatment of chronic hepatitis C
16. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha nonresponders
17. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection
18. The molecular basis of the specific anti-influenza action of amantadine
19. Ion channel activity of influenza A virus M2 protein: Characterization of the amantadine block
20. In vitro effect of amantadine and interferon-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus infected patients
21. Use of high-dose interferon in the treatment of chronic hepatitis C
22. Hepatitis C viral dynamics and the antiviral efficacy of interferon-α therapy
23. Dose-dependent acute clearance of hepatitis genotype 1 virus with interferon alfa
24. Classification of chronic hepatitis: Diagnosis, grading and staging
25. Histological classification and quantitation of the severity of chronic hepatitis: Keep it simple
26. Randomized trial of interferon (2b plus ribavirin for 48 weeks or 24 weeks versus interferon (2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
27. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
28. Amantadine and Rebetron™ exert a synergistic antiviral effect on HCV replication in interferon-α non-responders with chronic hepatitis C
29. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C
30. Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C
31. Treatment of chronic hepatitis C with amantadine
32. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C
33. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C
34. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C and persistent viremia
35. Modelling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view
36. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis
37. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in nonresponders to standard therapy
38. Influence of ribavirin on the dynamics of hepatitis C viremia in interferon-alpha-treated patients with response or nonresponse